Business, energy, technology, markets and global industry news from Business News Today

UPBEAT trial

PharmaDeviceNews UPBEAT trial
Affinia Therapeutics’ AFTX-201 gene therapy is advancing through the UPBEAT trial after receiving FDA Orphan Drug designation for BAG3-associated dilated cardiomyopathy. Representative image.
Pharma & Biotech

Affinia Therapeutics advances AFTX-201 gene therapy for BAG3 dilated cardiomyopathy

Affinia Therapeutics gains FDA orphan status for AFTX-201 as the UPBEAT trial tests gene therapy for BAG3 dilated cardiomyopathy.

Read More
Pharma & Biotech

What Affinia Therapeutics’ UPBEAT trial reveals about the next phase of inherited heart failure gene therapy

Affinia Therapeutics has cleared AFTX-201 for a Canadian BAG3 DCM trial. Read why the gene therapy’s design and risks matter now.

Read More